Neuronetics Inc (STIM) (Q3 2026) Earnings Call Highlights: Revenue Jumps
Neuronetics Inc (STIM) reported Q3 2026 revenue of $42M, up 12.5% YoY, driven by Greenbrook's 20.1% growth. Gross margin expanded to 52.2%, and operating expenses decreased 12.6%, leading to positive adjusted EBITDA of $1.9M. NeuroStar revenue grew only 1.8% YoY, with session revenue declining. Cash balance decreased to $27.9M. Management expects full-year 2026 cash flow to be negative $10M to $12M.
How this was made
The 30-second read
Why it matters
The earnings beat may trigger short‑term buying interest, but investors should monitor cash position and occupancy trends.
Market read
First disclosure of Q3 earnings for a small‑cap medical‑device firm; actionable for traders watching earnings surprises.
What to watch
Potential headwinds from declining NeuroStar session revenue and reduced cash balance.
Background
Neuronetics reported its Q3 2026 earnings call, highlighting revenue growth, margin expansion, and operational improvements.
Ticker impact
Q3 2026 revenue rose 12.5% YoY to $42M and adjusted EBITDA turned positive at $1.9M.
likely upward pressure as the market prices in the earnings beat and margin expansion
The fresh earnings numbers exceed prior quarter performance and show margin improvement, prompting traders to consider buying.
Market effects
Positive earnings may lift the mental health device sector and related RCM service providers.
U.S. small‑cap biotech/medical device segment could see modest gains.
Limited to investors focused on niche neuro‑stimulation market.
Counterpoint
Despite revenue growth, cash burn and low clinic occupancy could pressure the stock if guidance weakens.
Key entities
- companyNeuronetics Inc
Provider of TMS therapy devices and services.
- executiveDan Rivers
CEO of Neuronetics who discussed growth drivers.
